Unizima establishes regional bioproduction facilities in low-income nations to manufacture biologics like vaccines and monoclonal antibodies, integrating these with local healthcare systems. This approach addresses the lack of access to essential medicines in emerging markets by providing affordable, locally produced biologics and skilled workforce training.
Funding
Funding not disclosed
Founders
Product
Problem
Many low-income nations lack access to essential biologics like vaccines and monoclonal antibodies due to broken global supply chains and limited local manufacturing capabilities. This disparity hinders equitable healthcare and leaves populations vulnerable to disease outbreaks.
Solution
Unizima establishes regional bioproduction facilities in emerging markets to manufacture affordable biologics, integrating these facilities with local healthcare systems. The company provides end-to-end solutions, including technical and strategic advice, workforce training, and access to advanced bioproduction technologies. By enabling local production, Unizima aims to bridge the gap between scientific innovation and access to medicines, fostering a more resilient and equitable global health landscape. Unizima leverages expertise and technology from Univercells to deliver cost-effective and sustainable biomanufacturing solutions.
Target Audience
Unizima serves biopharma manufacturers, governments, global health organizations, and funders involved in establishing or expanding biomanufacturing capabilities in emerging markets.
Features
- Advisory services for governments, multilateral institutions, manufacturers, and funders on technical, financial, and regulatory aspects of biomanufacturing projects.
- Workforce training programs to build a skilled talent pipeline for the biomanufacturing industry.
- Partnership facilitation between public and private sector organizations to catalyze biomanufacturing in emerging markets.
- Access to Univercells Group's advanced bioproduction technologies for low-cost, low-footprint manufacturing.
- Expertise in manufacturing strategy, investment analysis, engineering, biologics manufacturing, GMP, quality assurance, regulatory affairs, supply chain, and logistics.
- Support for fill & finish capabilities for biologics like insulin and biosimilars.
- Business case simulation for contract manufacturing operations.